QPS DMPK provides a dedicated team of senior scientists to help select, design and conduct the appropriate ADME studies
for your specific compounds and therapeutic targets.
Working with QPS DMPK is a collaborative and consultative
endeavor that also incorporates our operational effectiveness
and dedication to customer service.
Partnering with QPS for a well-conceived and executed IND-enabling preclinical program will provide you with a detailed
assessment of your drug candidate and the most agile, flexible and timely pathway to filing an IND.
Whether your focus is on small molecules, proteins, bio-therapeutics, vaccines, or gene therapy, QPS provides a full range of bioanalytical solutions to support drug development from discovery through clinical development and filing.
Is your clinical trial in jeopardy? KCR's comprehensive rescue support will expeditiously steer it back on track. Taking over each rescue study on a case-by-case basis, our team of experts quickly analyze its status and provide accurate solutions to bring it back on track in a timely manner maintaining its safety,efficacy, and validity.
At QPS, translational medicine brings together leading-edge technologies and pharmaceutical research and development experience to create a business service unit that works efficiently to advance your drug development program.
To support research and development in different stages of biopharmaceutical compounds and products, QPS offers biomarker services in different global competence centers using
a wide range of technology platforms to support programs in any therapeutic area. QPS biomarker capabilities range from small molecule analysis to whole cell characterization.
Clinical Research Organization Services | Contract Research Company - PepgraPEPGRA Healthcare
Pepgra is a global contract research organization and drug development services company. It provides various phases of clinical research trials services to pharmaceutical and biotechnology companies to help reduce the time and costs associated with drug development.
Contact Us:
Website : https://bit.ly/33Fwsye
Email us: sales.cro@pepgra.com
India: +91 9884350006
United Kingdom: +44- 74248 10299
Partnering with QPS for a well-conceived and executed IND-enabling preclinical program will provide you with a detailed
assessment of your drug candidate and the most agile, flexible and timely pathway to filing an IND.
Whether your focus is on small molecules, proteins, bio-therapeutics, vaccines, or gene therapy, QPS provides a full range of bioanalytical solutions to support drug development from discovery through clinical development and filing.
Is your clinical trial in jeopardy? KCR's comprehensive rescue support will expeditiously steer it back on track. Taking over each rescue study on a case-by-case basis, our team of experts quickly analyze its status and provide accurate solutions to bring it back on track in a timely manner maintaining its safety,efficacy, and validity.
At QPS, translational medicine brings together leading-edge technologies and pharmaceutical research and development experience to create a business service unit that works efficiently to advance your drug development program.
To support research and development in different stages of biopharmaceutical compounds and products, QPS offers biomarker services in different global competence centers using
a wide range of technology platforms to support programs in any therapeutic area. QPS biomarker capabilities range from small molecule analysis to whole cell characterization.
Clinical Research Organization Services | Contract Research Company - PepgraPEPGRA Healthcare
Pepgra is a global contract research organization and drug development services company. It provides various phases of clinical research trials services to pharmaceutical and biotechnology companies to help reduce the time and costs associated with drug development.
Contact Us:
Website : https://bit.ly/33Fwsye
Email us: sales.cro@pepgra.com
India: +91 9884350006
United Kingdom: +44- 74248 10299
An overview of our Technology Accelerator business model. We describe a hybrid model leveraging minimally-dilutive funding and experienced pharmaceutical management to “de-risk” and drive projects to IND. Our area of expertise is prodrugs and infectious diseases (www.tsrlinc.com).
The Integrated Early Drug Development Platform White PaperCovance
Is it possible to deal with the explosion of complexity in the early clinical development space? Is the traditional clinical pharmacology unit obsolete? The answers are yes and no, respectively. The optimal engine for early clinical development in the modern era is an integrated early drug development platform.
A well-conceived and executed IND-enabling preclinical program and completion of early clinical trials will provide you with a detailed assessment of your drug candidate including the most cost-effective and timely pathway to filing an IND and completion of the “proof-of-concept” studies. During execution of your IND-enabling program you will benefit from QPS’ operational strengths, strong scientific/regulatory pre-IND/IND support and drug development experience.
ExL Pharma Clinical Trials Phase I and Phase IIa Conference Brochure: Phase 1...bryonmain
There is a pill or treatment for almost everything, or at least, that is how it seems. However, the amount of effort that goes into a pill or treatment before it is launched is extensive, expensive and often inefficient.
Efficiency and innovation go hand-in-hand with R&D and the development of clinical trials, however, FDA regulations and clinical trial standardization end up stifling these two key factors. This leads to drawn out processes that cost companies hundreds of millions of dollars before the drugs hit the market. Efforts have been made to increase efficiency in phase I/IIA with some companies changing their clinical trial manifestos to suit the available patient population at clinical sites, but more emphasis should be placed on creating more efficient processes for first in human studies by optimizing pharmacokinetics/pharmacodynamics, dosage selection, technological advancements to improve efficacy and structured patient mapping to increase successful trial and patient recruitment opportunities.
This program will give delegates the opportunity to share proven strategies between companies to help increase efficiency in this space and streamline processes to cut down costs. This event will bring together large and small companies and experts in this space to share best practices to decrease the financial drain theses phases have on the overall clinical trial budget. Life science corporations need the most up-to-date tools and practices to increase success by streamlining processes, sharing successful biomarker strategies, anticipating dosing quantities, and optimizing healthy or specialty patient recruitment and retention. Current strategies include patient mapping before organizing and setting up a clinical space, tailoring early phase clinical trials to patient populations, purchasing biological samples from collection companies, and trying to accelerate the process by submitting for breakthrough therapy designation.
Top Reasons To Attend
Identify Compound Development Strategies to Optimize Success in Clinical Trials
Learn Best Practices for Early Decision-Making Through Analysis of Biomarker Utility in Drug Development
Utilize Analytical Technology to Evaluate Multiple Configurations of a Small Molecule to Increase the Feasibility of Drug in Clinical Trials
Implement Adaptive Design in Proof of Concept Studies to Increase Efficiency, Decrease Time and Decrease Overall Cost
Explore the Seamless Development of Phase I to Phase II in Clinical Trials
NINE Case Studies and a Panel Session on Early Phase Clinical Trial Strategies
Chemometrics, Pharmacometrics and Econometrics Dimensions_of_QualityAjaz Hussain
25 May 2012 Basel, Switzerland. A philosophical exploration - Scientific understanding and risk-based regulatory decisions on Quality by Design. How good are the scientific explanations in regulatory submissions? Scientific explanations yield understanding; quality of explanations differ.What role can Chemometrics, Pharmacometics and Econometrics play? Understanding multidisciplinary (cGMP, CMC, Clin. Pharm., Tox., Clinical, Public Health) perspectives on risk is important. Opportunities; only when the disciplinary divides are bridged. Within the regulatory realm how we set specifications and assess risk have progressed incrementally; at this rate the Vision 2020 may be expected to be visible broadly over time, by 2020?
Visioning the Next Decade: NIPTE-FDA CollaborationAjaz Hussain
NIPTE Seminar at US FDA, 16 March 2016.
QBR as an Organizing Principle for the Proposed NIPTE Center of Excellence for Pharmaceutical Formulations (CEPF)
Our profound expertise in Neuroscience and two decades of experience in contract research result in a sustainable advantage for our customers. QPS offers you a sophisticated range of validated transgenic and non-transgenic in vivo and in vitro models to guarantee that your new chemical or biological compounds are profiled in depth.
A well-conceived and executed preclinical and clinical
radiolabeled ADME program will provide you with a detailed
assessment of the total fate (mass balance, route, and rate of excretion,
tissue distribution, metabolic pathways, and identity and quantity of
metabolites) of your drug candidate to support regulatory submissions.
An overview of our Technology Accelerator business model. We describe a hybrid model leveraging minimally-dilutive funding and experienced pharmaceutical management to “de-risk” and drive projects to IND. Our area of expertise is prodrugs and infectious diseases (www.tsrlinc.com).
The Integrated Early Drug Development Platform White PaperCovance
Is it possible to deal with the explosion of complexity in the early clinical development space? Is the traditional clinical pharmacology unit obsolete? The answers are yes and no, respectively. The optimal engine for early clinical development in the modern era is an integrated early drug development platform.
A well-conceived and executed IND-enabling preclinical program and completion of early clinical trials will provide you with a detailed assessment of your drug candidate including the most cost-effective and timely pathway to filing an IND and completion of the “proof-of-concept” studies. During execution of your IND-enabling program you will benefit from QPS’ operational strengths, strong scientific/regulatory pre-IND/IND support and drug development experience.
ExL Pharma Clinical Trials Phase I and Phase IIa Conference Brochure: Phase 1...bryonmain
There is a pill or treatment for almost everything, or at least, that is how it seems. However, the amount of effort that goes into a pill or treatment before it is launched is extensive, expensive and often inefficient.
Efficiency and innovation go hand-in-hand with R&D and the development of clinical trials, however, FDA regulations and clinical trial standardization end up stifling these two key factors. This leads to drawn out processes that cost companies hundreds of millions of dollars before the drugs hit the market. Efforts have been made to increase efficiency in phase I/IIA with some companies changing their clinical trial manifestos to suit the available patient population at clinical sites, but more emphasis should be placed on creating more efficient processes for first in human studies by optimizing pharmacokinetics/pharmacodynamics, dosage selection, technological advancements to improve efficacy and structured patient mapping to increase successful trial and patient recruitment opportunities.
This program will give delegates the opportunity to share proven strategies between companies to help increase efficiency in this space and streamline processes to cut down costs. This event will bring together large and small companies and experts in this space to share best practices to decrease the financial drain theses phases have on the overall clinical trial budget. Life science corporations need the most up-to-date tools and practices to increase success by streamlining processes, sharing successful biomarker strategies, anticipating dosing quantities, and optimizing healthy or specialty patient recruitment and retention. Current strategies include patient mapping before organizing and setting up a clinical space, tailoring early phase clinical trials to patient populations, purchasing biological samples from collection companies, and trying to accelerate the process by submitting for breakthrough therapy designation.
Top Reasons To Attend
Identify Compound Development Strategies to Optimize Success in Clinical Trials
Learn Best Practices for Early Decision-Making Through Analysis of Biomarker Utility in Drug Development
Utilize Analytical Technology to Evaluate Multiple Configurations of a Small Molecule to Increase the Feasibility of Drug in Clinical Trials
Implement Adaptive Design in Proof of Concept Studies to Increase Efficiency, Decrease Time and Decrease Overall Cost
Explore the Seamless Development of Phase I to Phase II in Clinical Trials
NINE Case Studies and a Panel Session on Early Phase Clinical Trial Strategies
Chemometrics, Pharmacometrics and Econometrics Dimensions_of_QualityAjaz Hussain
25 May 2012 Basel, Switzerland. A philosophical exploration - Scientific understanding and risk-based regulatory decisions on Quality by Design. How good are the scientific explanations in regulatory submissions? Scientific explanations yield understanding; quality of explanations differ.What role can Chemometrics, Pharmacometics and Econometrics play? Understanding multidisciplinary (cGMP, CMC, Clin. Pharm., Tox., Clinical, Public Health) perspectives on risk is important. Opportunities; only when the disciplinary divides are bridged. Within the regulatory realm how we set specifications and assess risk have progressed incrementally; at this rate the Vision 2020 may be expected to be visible broadly over time, by 2020?
Visioning the Next Decade: NIPTE-FDA CollaborationAjaz Hussain
NIPTE Seminar at US FDA, 16 March 2016.
QBR as an Organizing Principle for the Proposed NIPTE Center of Excellence for Pharmaceutical Formulations (CEPF)
Our profound expertise in Neuroscience and two decades of experience in contract research result in a sustainable advantage for our customers. QPS offers you a sophisticated range of validated transgenic and non-transgenic in vivo and in vitro models to guarantee that your new chemical or biological compounds are profiled in depth.
A well-conceived and executed preclinical and clinical
radiolabeled ADME program will provide you with a detailed
assessment of the total fate (mass balance, route, and rate of excretion,
tissue distribution, metabolic pathways, and identity and quantity of
metabolites) of your drug candidate to support regulatory submissions.
QPS is a GLP/GCP-compliant contract research organization (CRO) supporting discovery, preclinical and clinical drug development. We provide quality services to pharmaceutical and biotechnology clients worldwide.
When your focus is small molecules, biomarkers, or protein biotherapeutics,
QPS’ LC-MS/MS laboratories provide a full range of
bioanalytical solutions to support drug development
from discovery through clinical development.
PRINCIPLES OF DRUG DISCOVERY & DEVELOPMENT.pptxDharaMehta45
Principles of Drug Discovery & Development
Presented by…
Name – Dhara Mehta
Subject – PDTT
UNIT - 1
CONTENTS
Introduction
01
What is a "new drug"?....(CDSCO)
Phases
1) Target Identification
Target Identification Tools
• Animal models
• Biomarkers
• Expression Profile
• Cell-line
• Data banks
Properties of Ideal Target
Target Identification Strategies
• Gene Expression profiling: Genomics
• Focussed Proteomics
• Metabolic pathways analysis: MolecularBiology
• Phenotype analysis
• Genetic association
Target identification strategies
• Inverse Docking: It is a computational docking program in which a specific small molecule of interest is tested against a library of receptor structures.
• Bio informatics: It derives knowledge from computational analysis of biological data. It includes information stored in genetic code, patients statistics and scientific literature.
Limitation
• Drugs which do not act through receptors- Antacids, Osmotic diuretics, Alkylating agents, Psoralens and Activated charcoal can not be recognised
Target Validation
Hit Identification
Source of Lead
Source of leads: Animal
Source of leads: Microrganisms
Lead Generation Techniques
Molecular Modeling
Biotechnology
Genetic medicine
Immunopharmacology
SCREENING
Desired Characteristics of the Assay
Virtual screening (VS)
Target based virtual screening (TBVS
Ligand based virtual screening (LBVS).
Lipinski Rule of Five
• Poor absorption or permeation are more likely when there are:
1) More than 5 H-bond donors
2) The molecular weight is over 500
3) The CLog P is over 5 (or MLOGP is over 4.15)
4) The sum of N's and O's is over 10
• Substrates for transporters and natural products are exceptions.
Ligand based virtual screening (LBVS)
HIGH THROUGH PUT SCREENING (HTS)
The Real Screening
It is the process of testing a large number of diverse chemical structures against disease targets to identify "hits".
• Compared to traditional screening methods, HTS is characterised by:
• 1. Simplicity
• 2. Rapidness
• 3. High information harvest
• 4. Based on ligand-target interaction principle
HIGH THROUGH PUT SCREENING...
End results of screens:
Lead Optimization
Lead Optimisation
Lead Optimisation...Various steps:
• 1. Identification of the Pharmacophore (relevant groups on a molecule that interact with a receptor and are responsible for the biological activity
• 2. Functional group modification:Modification of the group may enable or disable certain biological effects.
• 3. S.A.R
Quantitative structure-activity relationships (QSAR-rational drug design)
6. Molecular graphics-based drug design
• To find a structure match, a computer technology called DOCKING is used.
• It is the computer-assisted movement of a terminal-displayed molecule into its receptor.
• Docking algorithms deal with ligand conformation prediction and orientation within the target active site.
• It predicts the various forces acting between target and ligand.Scoring function is a mathematical
At QPS, CSF Sampling brings together leading-edge technologies and pharmaceutical research and development to reveal pharmacokinetic information about drug concentrations.
The QPS Bioanalysis General presentation is a summary of our capabilities in Neuropharmacology, Toxicology, DMPK, Bioanalytical, Translational Medicine, and Dermal and Transdermal Preclinical services.
When your focus is Biotherapeutics, QPS’ Global Laboratories provide a full range of bioanalytical solutions to support immunogenicity evaluations during drug development from discovery through clinical development and filing.
QPS Missouri's Negative Pressure Room.
A negative pressure room uses lower air pressure than the
rooms surrounding it to allow outside air into the facility.
This traps and keeps harmful particles from leaving the
potentially contaminated area.
QPS Regulated Bioanalysis of Antibody Drug ConjugatesQPS Holdings, LLC
PK profiling reflects molecular complexity. Since 2001 QPS’ bioanalytical teams have contributed to ADC drug development,
supporting the filing of one of the first drug targeting
programs and continue to develop customized
strategies for novel conjugate molecules.
This white paper focuses on overcoming the challenges of participating in a pediatric trial. One of the biggest issues is that it is difficult to enroll participants in pediatric trials. Read these 5 strategies to help make it easier to enroll trial participants and complete successful trials.
In recent years, the pharmaceutical industry has witnessed increased political interest and attention due to the increased recognition of the economic importance and financial impact of healthcare as a component of national budgets. Biologic drugs (biologics) have attracted the attention of politicians since biologics have moved out of the niche pharmaceutical arena to contribute 17% of global pharmaceutical sales, representing revenues of more than $120bn in 2009. The market for biologics is growing at twice the rate of pharmaceutical drugs, placing significant cost pressures on government, employers, insurers, and patients. Government and insurers are using several strategies to contain costs but must ensure that the financial burden placed on patients does not restrict access to the health care system. Establishing a regulatory pathway for ‘follow-on’ biologics (biosimilars) was therefore felt to be necessary by many stake holders to encourage competition and reduce prices. Many pharmacutical companies both large and small - are expecting their bottom line growth to be driven by biosimilars and are channeling their R&D budgets to compete in what – according to many - is going to be one of the hottest areas in a radically changing global pharmaceutical market.
Three Lessons to Help Accelerate Pharmaceutical Breakthroughs for CNS DisordersQPS Holdings, LLC
"Developing therapies for diseases of the central nervous system (CNS) presents special challenges directly related to the complexity of the human brain and its function of integrating our communications with the outside world. Animal models of human neurological and psychiatric disorders are scarce, because many of these human diseases do not naturally occur in animals, and their study necessitates either specific manipulation (induced models) or the production of genetically modified rodents (transgenic and KO models). Even with these models, it remains unclear, what behavioral domain really resembles higher brain function in humans, and how we can interpret animal data on cognition, emotion, social interaction or activities of daily living.
Furthermore, in contrast with other organs, the CNS is sequestered from the general circulation by the blood brain barrier (BBB), potentially preventing many compounds from reaching their intended target. Quantifying how much of and how long a compound resides in the CNS is difficult and indirect. Therefore, the assessment of target engagement calls for specific techniques and know-how. While animal models provide some information as to how well a given compound accesses the brain, this data cannot always be translated directly to humans. Insufficient knowledge of target-compound interaction may be a major cause of failure in drug development for CNS disorders.
QPS understands the specific challenges of translation from animal models to human clinical application. Our extensive experience in CNS affords us a clear view of its complexities and its current global clinical study environment. Our direct links with the international scientific community and close relationships with key opinion leaders worldwide, together with our dedicated experts, original strategies and operational transparency, are keys to the effective execution of CNS programs for our clients."
The Nobel Prize for the discovery that double-stranded RNAs (dsRNAs) can trigger silencing of complementary messenger RNA sequences was awarded in 1998 and the term ‘RNA interference’ (RNAi) was born, opening the door to a completely novel and untapped market within the pharmaceutical industry. Shortly thereafter, short dsRNAs — or short interfering RNAs (siRNAs) — were generated artificially and used to demonstrate that this process also occurs in mammalian cells. The knowledge that small strands of RNAs can affect gene expression has had a tremendous impact on basic and applied research, and RNAi is currently one of the most promising new approaches for disease therapy. In 2004, only six years after the discovery of RNAi, the first siRNA-based human therapeutics — developed to treat wet age-related macular degeneration — entered phase I clinical trials. RNAi is one of the fastest advancing fields in biology, and the flow of discovery gives true meaning to the expression ‘from the bench to the bedside'.
Sometimes practical or ethical considerations dictate whether healthy volunteers or patients should be recruited for a particular study. But there are usually sound scientific arguments for collecting PK data from actual patients, to supplement or substitute for PK data obtained from human healthy volunteers during the first phases of drug development. Knowing to what extent the results obtained in healthy volunteers – if available - can be extrapolated to the intended treatment population is critical. The US FDA has recognized the importance of PK studies for determining drug concentration-time profiles in target patient populations.
This white paper focuses on the 505(b)(2) New Drug Approval (NDA) regulatory pathway, which relies on the public literature of clinical studies and/or the FDA's filing of safety and efficacy data for a previously approved drug.
Topical Transdermal Delivery Systems (TDDS) are designed to treat systemic medical conditions or localized joint or muscle conditions using the skin as the route of drug delivery. Whereas dermatologic topical formulations (foams, creams, lotions, ointments, gels, etc.) target skin diseases, Transdermal drug delivery offers important advantages over other routes of administration. It is particularly useful for circumventing liver first-pass metabolism, as an alternative to oral products, for non-invasive localized muscle and joint treatments, to improve and simplify patient compliance, and to allow for discontinuation of drug delivery by removing the patch in the event of adverse drug reactions. TDDS have become successful alternatives for delivering medications to young children, the elderly and the infirm.
ICP-MS detects elements instead of molecules. With the exception of a few elements (C, H, N, O and the noble gases), all elements can be detected. A specific element serves as a tag for the drug molecule of interest, thus enabling quantitation of this drug molecule in a particular matrix. The technique is highly linear and can be used quantitatively for a broad concentration range. Sample processing is relatively easy and throughput times are short, resulting in fast turnaround times.
Large Molecule Bioanalysis: LC-MS or ELISA? A Case StudyQPS Holdings, LLC
Both ligand binding assays (LBA) and mass spectrometry
(MS) methods are widely used in routine bionalysis with expanded applications of MS to large molecules in
the years ahead. In this presentation, PK parameters in the rart for three monoclonal antibodies (mAbs) are compared as derived from plasma concentration data as measured by LBA or Immunocapture LC-MS/MS.
A well-conceived and executed clinical radiolabelled ADME program will provide you with a detailed assessment of the total fate (mass balance, route and rate of excretion, tissue distribution, metabolic pathways, and identity and quantity of metabolites) of your drug candidate to support regulatory submissions. This presentation explains in 10 steps how we conduct a Human Mass Balance Study at QPS.
At QPS Netherlands (QPS-NL), we have expanded our early stage clinical research capabilities in 2012 to include respiratory clinical trials. To this end, QPS-NL is collaborating with Dr. Zuzana Diamant, research pulmonologist and clinical pharmacologist. Professor Diamant has over 20 years of experience in clinical respiratory trials, with a focus on phases 0, I and II proof-of-concept studies in respiratory allergy, asthma and COPD.
Zuzana Diamant is Guest Professor at Skane University, Lund, Sweden; collaborating scientist at University Medical Centre Groningen, Dept. of General Practice; and a member of several international scientific networks including the ATS/ERS taskforce for bronchoprovocation testing (allergen challenge) and two editorial boards.
Together with our dedicated research physician and epidemiologist Dr. Tjeert Mensinga, our well-trained research team, and onsite laboratory biomarker facilities, this collaboration now enables us to perform consultancy services. These include study design, study set up and the conduct of respiratory POC-studies combining clinical disease models (e.g. inhaled and nasal allergen and LPS challenges) with non-invasive airway samplings (e.g. nasal lavage, nasal brushings, sputum analysis, exhaled airway analysis) to test targeted therapies.
Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...QPS Holdings, LLC
Traditionally, the Netherlands has a major role in the conduct of early stage clinical drug trials. The Netherlands perform well on approval time, quality and expertise; all key drivers for early clinical trial location choice. QPS Netherlands has its own state-of-the-art clinical pharmacology unit (CPU) with 58 beds, an advanced bioanalytical laboratory, radiochemistry laboratory, GMP pharmacy, and a medical recruitment and examination center. The company is strategically located at the University Medical Center Groningen (UMCG). The clinical pharmacology beds and bioanalytical laboratories are highly integrated, resulting in a very efficient operational environment. QPS Netherlands has several strategic partners that further support its operations. Cooperation with these strategic partners gives QPS Netherlands a clear competitive advantage in specific therapeutic fields such as Female Health Care, CNS, Pain and Pulmonary Medicine. Key customers include several global Top 10 pharmaceutical companies and all of the global Top 5 biotechnology companies. Numerous small and medium-sized pharmaceutical and biotechnology companies complete QPS Netherlands’ customer base. Projects at QPS Netherlands range from full-service Phase I/IIa drug development, including strategic consultancy, to dedicated single task projects with high value added.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Couples presenting to the infertility clinic- Do they really have infertility...
QPS DMPK
1. TIME IS OF THE ESSENCE IN DRUG DEVELOPMENT.
CONTACT THE QPS BUSINESS DEVELOPMENT TEAM TODAY!
CALL +1 512 350 2827 EMAIL infobd@qps.com
DMPK
A flexible approach to
QPS DMPK PROVIDES A DEDICATED
TEAM OF SENIOR SCIENTISTS TO HELP SELECT,
design and conduct the appropriate ADME studies
for your specific compounds and therapeutic targets.
Working with QPS DMPK is a collaborative and consultative
endeavor that also incorporates our operational effectiveness
and dedication to customer service.
2. Fargo, ND, USA
Dermal and Transdermal
Research Laboratory (DTRL)
Groningen and Leeuwarden,
The Netherlands
Bioanalysis (BA)
Clinical Research Services (CRS)
Translational Medicine (TLM)
Suzhou and Shanghai,
China
Bioanalysis (BA)
Clinical Research Services (CRS)
Miami, FL, USA
Clinical Research
Services (CRS)
Hyderabad, India
Bioanalysis (BA)
Clinical Research
Services (CRS)
Taipei, Taiwan
Bioanalysis (BA)
Clinical Research Services (CRS)
Toxicology (TOX)
Newark, DE, USA
Bioanalysis (BA)
Clinical Research Services (CRS)
DMPK
Translational Medicine (TLM)
Global Headquarters for
QPS Holdings LLC
Graz, Austria
Clinical Research Services (CRS)
DMPK
Histology Services
Neuropharmacology
Rare Disease
Rodent Biobank
Springfield, MO, USA
Clinical Research
Services (CRS)
Macro & Micro Autoradiography
One of QPS’ main services in DMPK is the combined mass
balance, biliary excretion, PK, and QWBA studies.
f Increased efficiency by using a single study protocol
f Better study oversight with an integrated study report
f Elimination of the possibility of radiolabel degrading over
an extended period of time between the two studies
f Metabolite profiling and identification can be done using
the samples from the same study
f Micro-autoradiography provides insight into sub-cellular
tissue distribution
Biotransformation
QPS biotransformation studies determine how a molecule
may be altered by the action of enzymes. These study
types include:
f In vitro metabolic stability in hepatic subcellular fractions
to determine intrinsic clearance
f In vitro comparison of metabolite formation in animal
and human hepatic preparations, using non-labeled and
radio-labeled test articles
f In vivo metabolite profiling, identification and
quantification using samples collected from animal PK,
mass balance excretion studies, and human AME studies
to satisfy Metabolites in Safety Testing (MIST)
Protein Binding
QPS protein binding studies determine the extent of
protein binding in various plasma species and tissues.
f Methods: equilibrium dialysis (RED, Harvard device, 96-
well HTD), ultrafiltration, and ultracentrifugation
f Discovery screening, in vitro protein binding for IND, and
ex vivo studies in clinical phases
f Experience in compounds with very high binding, stability
issues, or non-specific issues
Drug-Drug Interaction
QPS drug interaction studies determine the potential of
a substance to alter cytochrome P450 activity. Studies
conducted to assess inhibition and induction potential
to support discovery and development of new drug
candidates are:
f In vitro inhibition characterization in human liver
microsomes or hepatocytes to determine reversible or
time dependent IC50
f In vitro mechanistic characterization of reversible
inhibitory rate constants Ki
f Identification of the reversible mechanism of inhibition as
competitive, non-competitive or uncompetitive
f In vitro mechanistic characterization of time dependent
inhibition Kinact
and KI
f Identification of the mechanism of time dependent
inhibition as metabolite mediated via covalent
modification or due to tight binding effect of substrate
f In vitro characterization of CYP1A2, CYP2B6, and CYP3A4
induction potential in human hepatocytes based on
mRNA and/or CYP activity using isoform selective probe
substrates
QPS is a Global CRO with locations around the world
WWW.QPS.COM